Immuneering to Present at the Jefferies Global Healthcare Conference
29 mai 2024 16h05 HE
|
Immuneering Corporation
Immuneering to Present at the Jefferies Global Healthcare Conference
Immuneering Announces Positive Initial Phase 1 Pharmacokinetic, Pharmacodynamic and Safety Data for IMM-1-104 Universal-RAS Program; Accelerates Study Timeline
18 avr. 2023 09h00 HE
|
Immuneering Corporation
Data presented at AACR Annual Meeting support IMM-1-104's potential to address a broad population of patients with RAS mutant tumorsIMM-1-104 well tolerated with no dose limiting toxicities (DLTs) or...
Immuneering Announces Participation in March Investor Conferences
28 févr. 2023 08h00 HE
|
Immuneering Corporation
CAMBRIDGE, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company developing medicines for broad populations of cancer patients with an...
Immuneering to Report Fourth Quarter and Full Year 2022 Financial Results and Business Updates
27 févr. 2023 08h00 HE
|
Immuneering Corporation
CAMBRIDGE, Mass., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company developing medicines for broad populations of cancer patients with an...